C4 Therapeutics (CCCC) EBT: 2019-2025
Historic EBT for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$32.2 million.
- C4 Therapeutics' EBT fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.0 million, marking a year-over-year decrease of 13.05%. This contributed to the annual value of -$105.2 million for FY2024, which is 19.84% up from last year.
- Per C4 Therapeutics' latest filing, its EBT stood at -$32.2 million for Q3 2025, which was down 23.62% from -$26.0 million recorded in Q2 2025.
- C4 Therapeutics' EBT's 5-year high stood at -$15.7 million during Q4 2021, with a 5-year trough of -$35.9 million in Q2 2023.
- Its 3-year average for EBT is -$29.2 million, with a median of -$28.4 million in 2024.
- Per our database at Business Quant, C4 Therapeutics' EBT crashed by 106.00% in 2021 and then surged by 50.68% in 2024.
- Over the past 5 years, C4 Therapeutics' EBT (Quarterly) stood at -$15.7 million in 2021, then tumbled by 75.07% to -$27.4 million in 2022, then declined by 25.77% to -$34.5 million in 2023, then grew by 0.10% to -$34.4 million in 2024, then crashed by 30.41% to -$32.2 million in 2025.
- Its EBT stands at -$32.2 million for Q3 2025, versus -$26.0 million for Q2 2025 and -$26.3 million for Q1 2025.